Madam, Sir, Dear Shareholder, With this letter, we ask you to continue to provide Nicox with your valuable support by voting at the Extraordinary General Meeting convened for July 11, 2022. In 2021, the Company consolidated its R&D team with the recruitment of Doug Hubatsch as Chief Scientific Officer. With this recruitment, the Company now has a strong management team to lead post-Phase 3 activities while continuing to build a targeted and clinically relevant ophthalmic pipeline. In 2021, the Company’s resources were particularly focused on the phase 3 program for NCX 470, consisting of two pivotal phase 3 clinical studies, the Mont Blanc and Denali studies, in patients with open-angle glaucoma or ocular hypertension. This month, we announced that the results of the first phase 3 Mont Blanc study will be available sooner than expected, in November 2022. The Company is funded until the fourth quarter of 2023. Your vote and your support for the Extraordinary General Meeting are very important to give the Company the means of action to continue its development. @nicox.com or by telephone on 04 97 24 53 28. With kind regards, Andreas Segerros, Managing Director